• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/10/21 11:03:22 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ITGR alert in real time by email
    SC 13G/A 1 tv01136-integerholdingscorp.htm SCHEDULE 13G/A integerholdingscorp

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 11)*

    Name of issuer:  Integer Holdings Corp.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  45826H109

    Date of Event Which Requires Filing of this Statement: December 31, 2020

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  45826H109

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    60,142

    7.  SOLE DISPOSITIVE POWER

    3,404,370

    8.  SHARED DISPOSITIVE POWER

    87,059

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,491,429

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    10.62%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Integer Holdings Corp.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    2595 Dallas Parkway
    Suite 310
    Frisco, Texas 75034

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    45826H109

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

    3,491,429

      (b) Percent of Class:

    10.62%

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  0

    (ii)  shared power to vote or direct to vote:  60,142

    (iii)  sole power to dispose of or to direct the disposition of:  3,404,370

    (iv)  shared power to dispose or to direct the disposition of:  87,059

    Comments:

     

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    Not applicable

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    See Attached Appendix A

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 8, 2021

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

     

     

    Appendix A

    Subsidiary:

    Vanguard Asset Management, Limited

    Vanguard Fiduciary Trust Company

    Vanguard Global Advisors, LLC

    Vanguard Group (Ireland) Limited

    Vanguard Investments Australia Ltd

    Vanguard Investments Canada Inc.

    Vanguard Investments Hong Kong Limited

    Vanguard Investments UK, Limited

    *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G

     

    Get the next $ITGR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ITGR

    DatePrice TargetRatingAnalyst
    10/24/2025Buy → Hold
    Argus
    10/24/2025$80.00Overweight → Equal Weight
    Wells Fargo
    10/24/2025$77.00Buy → Neutral
    Citigroup
    10/24/2025$87.00Buy → Neutral
    BofA Securities
    10/24/2025Buy → Hold
    The Benchmark Company
    5/22/2025$140.00Neutral → Buy
    Citigroup
    3/28/2025$145.00Outperform
    Raymond James
    2/21/2025Outperform → Perform
    Oppenheimer
    More analyst ratings

    $ITGR
    SEC Filings

    View All

    Integer Holdings Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Integer Holdings Corp (0001114483) (Filer)

    11/4/25 8:01:46 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Holdings Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Integer Holdings Corp (0001114483) (Filer)

    10/24/25 8:01:29 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form 10-Q/A filed by Integer Holdings Corporation

    10-Q/A - Integer Holdings Corp (0001114483) (Filer)

    10/24/25 7:36:36 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Integer Holdings Corporation Board Authorizes $200 Million Share Repurchase Program

    PLANO, Texas, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device contract development and manufacturing organization, today announced that its Board of Directors has authorized a share repurchase program of up to $200 million of the Company's outstanding common stock. "This share repurchase program reflects the confidence of the Board and management in our strategy, financial position, and ability to generate strong free cash flows," said Payman Khales, Integer's president and CEO. The Company intends to primarily utilize cash on hand and free cash flows to fund the share repurchase program. The timing and volume of share repurchases may

    11/4/25 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Payman Khales Assumes Role as Integer President and CEO

    ~ Planned Leadership Transition Completed ~ PLANO, Texas, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today shared that, as part of a planned transition originally announced in April 2025, Payman Khales has assumed the role of President and Chief Executive Officer. He also joins the company's Board of Directors. He succeeds Joseph Dziedzic, who is retiring after eight years of distinguished service as Integer President and CEO and will continue to serve as an advisor through March 31, 2026, to support a smooth transition. Mr. Khales joined Integer in 2018 as Preside

    10/24/25 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Holdings Corporation Reports Third Quarter 2025 Results

    ~ Continued strong sales and profit growth in 3Q25 ~~ Updating 2025 sales and profit outlook; providing preliminary outlooks for 2026 and 2027 ~ PLANO, Texas, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended September 26, 2025. Third Quarter 2025 Highlights (compared to Third Quarter 2024, except as noted) Sales increased 8% to $468 million, with organic growth of 7%.GAAP operating income decreased $2 million to $56 million, a decrease of 3%. Non-GAAP adjusted operating income increased $10 million to $86 million, an increase of 14%.GAAP income from continuing operations increased $3 million to $40 million, an

    10/23/25 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Financial Officer Smith Diron bought $74,967 worth of shares (1,116 units at $67.19), increasing direct ownership by 17% to 7,698 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    11/10/25 8:19:02 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Capps Cheryl C bought $106,720 worth of shares (1,600 units at $66.70), increasing direct ownership by 16% to 11,702 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    11/10/25 8:16:21 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    President & CEO Khales Payman bought $203,067 worth of shares (3,127 units at $64.94), increasing direct ownership by 16% to 22,865 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    10/30/25 4:05:07 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Integer Holdings downgraded by Argus

    Argus downgraded Integer Holdings from Buy to Hold

    10/24/25 2:15:30 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Holdings downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Integer Holdings from Overweight to Equal Weight and set a new price target of $80.00

    10/24/25 8:57:52 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Holdings downgraded by Citigroup with a new price target

    Citigroup downgraded Integer Holdings from Buy to Neutral and set a new price target of $77.00

    10/24/25 8:57:52 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Financial Officer Smith Diron bought $74,967 worth of shares (1,116 units at $67.19), increasing direct ownership by 17% to 7,698 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    11/10/25 8:19:02 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Capps Cheryl C bought $106,720 worth of shares (1,600 units at $66.70), increasing direct ownership by 16% to 11,702 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    11/10/25 8:16:21 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    President & CEO Khales Payman bought $203,067 worth of shares (3,127 units at $64.94), increasing direct ownership by 16% to 22,865 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    10/30/25 4:05:07 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Financials

    Live finance-specific insights

    View All

    Integer Holdings Corporation Reports Third Quarter 2025 Results

    ~ Continued strong sales and profit growth in 3Q25 ~~ Updating 2025 sales and profit outlook; providing preliminary outlooks for 2026 and 2027 ~ PLANO, Texas, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended September 26, 2025. Third Quarter 2025 Highlights (compared to Third Quarter 2024, except as noted) Sales increased 8% to $468 million, with organic growth of 7%.GAAP operating income decreased $2 million to $56 million, a decrease of 3%. Non-GAAP adjusted operating income increased $10 million to $86 million, an increase of 14%.GAAP income from continuing operations increased $3 million to $40 million, an

    10/23/25 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Announces Conference Call to Discuss Third Quarter 2025 Results

    PLANO, Texas, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR) announced today that it will webcast its conference call discussing financial results and business highlights for the third quarter ended Sept. 26, 2025, on Thursday, Oct. 23, 2025, at 8 a.m. CT / 9 a.m. ET. Other forward-looking and material information may also be discussed during this call. The company will issue a news release announcing financial results for the third quarter on Oct. 23 prior to the conference call. Conference call details: Date: Thursday, Oct. 23, 2025Time: 8 a.m. CT / 9 a.m. ETDomestic dial-in number: (800) 715-9871International dial-in number: (646) 307-1963Conference ID: 3

    9/25/25 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Holdings Corporation Reports Second Quarter 2025 Results

    ~ Continued strong sales and profit growth in 2Q25 ~ ~ Raising 2025 full year adjusted operating income and EPS outlook midpoint ~ PLANO, Texas, July 24, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended June 27, 2025. Second Quarter 2025 Highlights (compared to Second Quarter 2024, except as noted) Sales increased 11% to $476 million, with organic growth of 11%.GAAP operating income increased $5 million to $59 million, an increase of 9%. Non-GAAP adjusted operating income increased $10 million to $81 million, an increase of 15%.GAAP income from continuing operations increased $6 million to $37 m

    7/24/25 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ITGR
    Leadership Updates

    Live Leadership Updates

    View All

    Payman Khales Assumes Role as Integer President and CEO

    ~ Planned Leadership Transition Completed ~ PLANO, Texas, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today shared that, as part of a planned transition originally announced in April 2025, Payman Khales has assumed the role of President and Chief Executive Officer. He also joins the company's Board of Directors. He succeeds Joseph Dziedzic, who is retiring after eight years of distinguished service as Integer President and CEO and will continue to serve as an advisor through March 31, 2026, to support a smooth transition. Mr. Khales joined Integer in 2018 as Preside

    10/24/25 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Integer Appoints Michael Coyle to Board of Directors

    ~ New Director Brings Extensive Medical Device Industry Leadership and Technology Experience to Integer Board ~ PLANO, Texas, July 10, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced it has appointed Michael Coyle to its Board of Directors. Coyle brings more than 40 years of leadership in the medical device industry to Integer and joins the Board as a member of the Audit Committee, Compensation & Organization Committee, and Technology Strategy Committee. He most recently served as president and CEO of iRhythm Technologies, a digital healthcare company. Bef

    7/10/25 4:52:01 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Eargo Announces Strategic Additions to Board of Directors Following Patient Square Capital Becoming New Majority Shareholder

    SAN JOSE, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. ("Eargo" or the "Company") (NASDAQ:EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the appointments of several new directors following the closing of the Company's rights offering as previously announced on November 29, 2022. Patient Square Capital became the Company's majority owner upon closing of the rights offering and conversion of Patient Square's senior secured convertible notes per its investment in June 2022. As previously announced, following the completion of the rights offering, Patient Square has the right to nominate a number of directors t

    12/7/22 4:05:00 PM ET
    $EAR
    $ITGR
    $VAPO
    Medical Specialities
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    $ITGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Integer Holdings Corporation (Amendment)

    SC 13G/A - Integer Holdings Corp (0001114483) (Subject)

    2/9/24 9:59:01 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Integer Holdings Corporation (Amendment)

    SC 13G/A - Integer Holdings Corp (0001114483) (Subject)

    1/30/24 1:15:44 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Integer Holdings Corporation (Amendment)

    SC 13G/A - Integer Holdings Corp (0001114483) (Subject)

    2/10/23 2:42:23 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care